Overview
- Omada Health announced a planned capability to prescribe GLP-1s and other anti-obesity medications, integrating licensed obesity-trained providers into its existing behavioral weight program.
- The prescribing and medication-management service is designed for availability in all 50 states through a nationally scalable model.
- Leaders said the service will guide members through dose changes, potential side effects and medication switches to support persistence and safe use.
- Company analyses cited by Omada report stronger short-term weight loss in an Enhanced GLP-1 care track and relative weight maintenance after discontinuation compared with published benchmarks.
- The announcement accompanied Q3 results that included $68 million in revenue, up 49% year over year, and 831,000 members, up 53%, with executives calling the offering an employer and health plan add-on; prescriptions will be branded drugs filled at the member’s chosen pharmacy, not compounded.